FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
--

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Kathiresan Sekar</u>					2. Issuer Name and Ticker or Trading Symbol Verve Therapeutics, Inc. [VERV]								Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner								
(Last) (First) (Middle) C/O VERVE THERAPEUTICS, INC. 500 TECHNOLOGY SQUARE, SUITE 901						3. Date of Earliest Transaction (Month/Day/Year) 01/04/2022									X Officer (give title Other (specify below) Chief Executive Officer						
(Street) CAMBR (City)			02139 (Zip)		- 4. li	f Amer	ndmer	nt, Date o	of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
			Date	2. Transaction Date (Month/Day/Year		Execution Date,		3. Transaction Code (Instr. 8)					and Securities Beneficia Owned Fo		у	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)			
Common	Stock			01/04/2022		22		М		1,870	A	\$1	39	408,406		D					
Common Stock 01				01/04/	1/04/2022				S ⁽¹⁾		1,870	D	\$39	9.9	406,536		D				
Common Stock													80,9		97		I	Kathiresan Family 2021 Irrevocable Trust			
Common Stock															80,997		I		Sekar Kathiresa 2021 Irrevocab Trust		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned																					
(e.g., p 1. Title of Derivative Conversion Date Courity or Exercise (Month/Day/Year) (e.g., p 3. Transaction Date Execution Date, if any			4. Transa	ransaction Code (Instr.		5. Number of			sable and te	7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Numi derivati Securiti Benefic Owned Followi Reporte Transac (Instr. 4	ive ies cially ng ed ction(s)	10. Owners Form: Direct (I or Indire (I) (Instr	Beneficial Ownership ect (Instr. 4)				
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amou or Numb of Share	ber							
Stock Option (right to buy)	\$1.39	01/04/2022			M			1,870	(2)		04/14/2029	Common Stock	1,87	70	\$0.00 267		,425	D			

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 3, 2021.
- 2. The remaining shares underlying this option, which was granted on April 15, 2019 and commenced vesting on July 22, 2019, vest in equal monthly installments thereafter until July 22, 2023.

Remarks:

/s/ Andrew Ashe, as Attorneyin-Fact for Sekar Kathiresan

01/06/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.